Table 1.
Characteristics of participants: where applicable: mean ± standard deviation (minimum - maximum).
| Donepezil | Rivastigmine | p-value | |
|---|---|---|---|
| Numbers | 41 | 26 | – |
| Sex: male:female | 21: 20 (51%: 49%) |
16:10 (61.5%: 38.5%) |
0.458a |
| Age [years] | 72.7 ± 9.51 (53-88) |
72.1 ± 7.0 (53-86) |
0.772b |
| Time baseline to follow up [days] | 217.7 ± 64.8 (96-441) |
228.7 ± 80.2 (122-442) |
0.990c |
| Duration from start of AChE-I treatment to follow up [months] | 5.7 ± 2.4 (3-13) |
5.7 ± 2.1 (2-12) |
0.825c |
| Number of participants taking CYP2D6 inhibitors |
6 (5 x Citalopram; 1 x Carvedilol) |
n.a. | – |
| Number of participants taking CYP2D6 inducers |
none | n.a. | – |
| Weight [kg] n=37 (Donepezil) n=24 (Rivastigmine) |
69.5 ± 8.5 (50-83) |
68.2 ± 13.8 (47-90) |
0.671b |
| BMI [kg/m²] n=37 (Donepezil) n=24 (Rivastigmine) |
23.8 ± 3.0 (17.2-34.5) |
23.5 ± 3.6 (16.5-30.9) |
0.743b |
AChE-I, acetylcholinesterase inhibitor; n.a., not applicable; kg, participants' weight in kilogram; BMI, body mass index; p-values calculated from aChi-squared test, bt-test or cMann-Whitney-U-test.